Cytek Biosciences (CTKB) Stock
Spectral flow cytometry systems for biopharma research. Here's the price, business snapshot, and what's worth knowing about Cytek Biosciences in October 2026.
Cytek Biosciences (CTKB) develops spectral flow cytometry systems, reagents and analysis software used by research institutions, biopharma and clinical laboratories. Its instruments aim to measure many parameters per cell, supporting deeper immunophenotyping and single‑cell studies. The company’s revenue mix commonly combines one‑off instrument sales with recurring consumables and software licences, which can support steadier revenue as the installed base expands. Growth drivers include broader adoption of spectral cytometry, new product introductions and partnerships with pharmaceutical and diagnostic customers. Key risks are strong competition from established instrument makers, continued need for R&D investment, supply‑chain and manufacturing execution, and sensitivity to research spending cycles. As a small‑cap company (market capitalisation roughly $530m), CTKB may exhibit greater volatility and lower liquidity than larger peers. This summary is general educational information only and not personal advice; values can fall as well as rise.
Cytek Biosciences (CTKB) Stock Forecast
Analyst price target, next 12 months
$7.71
+31.4% vs today's $5.87
Price range over the last 12 months
Close to its 12-month high
Analysts covering Cytek Biosciences have a consensus 12-month target of $7.71, above the current price of $5.87.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 5 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Cytek Biosciences' stock, anticipating it will rise to $7.71.
Financial Health
Cytek Biosciences is performing well with strong revenue and cash flow, showing healthy profitability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Adoption of Spectral Cytometry
Spectral cytometry can enable higher‑parameter analysis, so broader adoption could support long‑term growth — though customer uptake and competition will influence outcomes.
Recurring Consumables Revenue
Consumables and software licences offer recurring revenue potential that can stabilise sales beyond instrument purchases, yet revenue can vary with research budgets.
Market & Competition
The addressable market spans academic, clinical and pharma customers, but Cytek faces established players and execution challenges; investors should watch commercial traction closely.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.